Literature DB >> 16489449

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.

Markus Kathmann1, Karsten Flau, Agnes Redmer, Christian Tränkle, Eberhard Schlicker.   

Abstract

The mechanism of action of cannabidiol, one of the major constituents of cannabis, is not well understood but a noncompetitive interaction with mu opioid receptors has been suggested on the basis of saturation binding experiments. The aim of the present study was to examine whether cannabidiol is an allosteric modulator at this receptor, using kinetic binding studies, which are particularly sensitive for the measurement of allosteric interactions at G protein-coupled receptors. In addition, we studied whether such a mechanism also extends to the delta opioid receptor. For comparison, (-)-Delta9-tetrahydrocannabinol (THC; another major constituent of cannabis) and rimonabant (a cannabinoid CB1 receptor antagonist) were studied. In mu opioid receptor binding studies on rat cerebral cortex membrane homogenates, the agonist 3H-DAMGO bound to a homogeneous class of binding sites with a KD of 0.68+/-0.02 nM and a Bmax of 203+/-7 fmol/mg protein. The dissociation of 3H-DAMGO induced by naloxone 10 microM (half life time of 7+/-1 min) was accelerated by cannabidiol and THC (at 100 microM, each) by a factor of 12 and 2, respectively. The respective pEC50 values for a half-maximum elevation of the dissociation rate constant k(off) were 4.38 and 4.67; 3H-DAMGO dissociation was not affected by rimonabant 10 microM. In delta opioid receptor binding studies on rat cerebral cortex membrane homogenates, the antagonist 3H-naltrindole bound to a homogeneous class of binding sites with a KD of 0.24+/-0.02 nM and a Bmax of 352+/-22 fmol/mg protein. The dissociation of 3H-naltrindole induced by naltrindole 10 microM (half life time of 119+/-3 min) was accelerated by cannabidiol and THC (at 100 microM, each) by a factor of 2, each. The respective pEC50 values were 4.10 and 5.00; 3H-naltrindole dissociation was not affected by rimonabant 10 microM. The present study shows that cannabidiol is an allosteric modulator at mu and delta opioid receptors. This property is shared by THC but not by rimonabant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489449     DOI: 10.1007/s00210-006-0033-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor.

Authors:  R A Leppik; S Lazareno; A Mynett; N J Birdsall
Journal:  Mol Pharmacol       Date:  1998-05       Impact factor: 4.436

Review 2.  International Union of Pharmacology. XII. Classification of opioid receptors.

Authors:  B N Dhawan; F Cesselin; R Raghubir; T Reisine; P B Bradley; P S Portoghese; M Hamon
Journal:  Pharmacol Rev       Date:  1996-12       Impact factor: 25.468

3.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Authors:  David J Rog; Turo J Nurmikko; Tim Friede; Carolyn A Young
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

4.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

Review 5.  Modulation of transmitter release via presynaptic cannabinoid receptors.

Authors:  E Schlicker; M Kathmann
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

6.  Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor.

Authors:  R A Leppik; A Mynett; S Lazareno; N J Birdsall
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

Review 7.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

8.  Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.

Authors:  L T Potter; C A Ferrendelli; H E Hanchett; M A Hollifield; M V Lorenzi
Journal:  Mol Pharmacol       Date:  1989-05       Impact factor: 4.436

9.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats.

Authors:  I Ulibarri; J A García-Sevilla; L Ugedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

View more
  106 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

Review 4.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 5.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 6.  Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives.

Authors:  Alison C Burggren; Anaheed Shirazi; Nathaniel Ginder; Edythe D London
Journal:  Am J Drug Alcohol Abuse       Date:  2019-07-31       Impact factor: 3.829

7.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 8.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 9.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.